8 Tips To Boost Your Pragmatic Free Trial Meta Game
Pragmatic Free Trial Meta
Pragmatic Free Trial Meta is a free and non-commercial open data platform and infrastructure that supports research on pragmatic trials. It is a platform that collects and shares clean trial data and ratings using PRECIS-2, allowing for multiple and diverse meta-epidemiological studies to examine the effects of treatment across trials that employ different levels of pragmatism as well as other design features.
Background
Pragmatic studies provide real-world evidence that can be used to make clinical decisions. However, the use of the term "pragmatic" is inconsistent and its definition and evaluation requires clarification. The purpose of pragmatic trials is to guide the practice of clinical medicine and policy choices, rather than verify a physiological hypothesis or clinical hypothesis. A pragmatic trial should try to be as close as possible to the real-world clinical practice, including recruitment of participants, setting up, delivery and execution of interventions, determination and analysis results, as well as primary analysis. This is a major distinction between explanatory trials, as described by Schwartz and Lellouch1 which are designed to test a hypothesis in a more thorough manner.
Trials that are truly pragmatic should avoid attempting to blind participants or healthcare professionals, as this may cause bias in estimates of treatment effects. The trials that are pragmatic should also try to recruit patients from a variety of health care settings, to ensure that their findings are generalizable to the real world.
Furthermore the focus of pragmatic trials should be on outcomes that are vital to patients, like quality of life or functional recovery. This is especially important when it comes to trials that involve invasive procedures or those with potentially serious adverse events. The CRASH trial29 compared a 2 page report with an electronic monitoring system for patients in hospitals with chronic heart failure. The trial with a catheter, however, used symptomatic catheter associated urinary tract infection as its primary outcome.
In addition to these characteristics pragmatic trials should also reduce trial procedures and data-collection requirements to cut costs and time commitments. Finally Source Webpage should strive to make their findings as applicable to real-world clinical practice as they can by making sure that their primary analysis is based on the intention-to-treat method (as described in CONSORT extensions for pragmatic trials).
Despite these guidelines, many RCTs with features that defy the concept of pragmatism have been mislabeled as pragmatic and published in journals of all types. This can result in misleading claims of pragmatism and the usage of the term needs to be standardized. The development of the PRECIS-2 tool, which provides an objective and standard assessment of pragmatic features is a great first step.
Methods
In a pragmatic trial it is the intention to inform policy or clinical decisions by showing how an intervention could be integrated into everyday routine care. This is different from explanatory trials that test hypotheses about the cause-effect relationship in idealised conditions. In this way, pragmatic trials may have lower internal validity than studies that explain and be more susceptible to biases in their design as well as analysis and conduct. Despite their limitations, pragmatic studies can be a valuable source of data for making decisions within the healthcare context.
The PRECIS-2 tool assesses the degree of pragmatism within an RCT by assessing it across 9 domains, ranging from 1 (very explicative) to 5 (very pragmatic). In this study, the recruitment, organization, flexibility in delivery, flexible adherence and follow-up domains received high scores, however the primary outcome and the procedure for missing data were not at the pragmatic limit. This suggests that it is possible to design a trial using excellent pragmatic features without damaging the quality of its results.
However, it is difficult to determine the degree of pragmatism a trial is, since the pragmatism score is not a binary quality; certain aspects of a trial may be more pragmatic than others. Additionally, logistical or protocol modifications during the course of an experiment can alter its pragmatism score. In addition, 36% of the 89 pragmatic trials discovered by Koppenaal and co. were placebo-controlled, or conducted prior to approval and a majority of them were single-center. Thus, they are not quite as typical and are only pragmatic when their sponsors are accepting of the lack of blinding in such trials.
A common aspect of pragmatic studies is that researchers try to make their findings more relevant by studying subgroups within the trial sample. This can lead to unbalanced comparisons and lower statistical power, which increases the risk of either not detecting or misinterpreting differences in the primary outcome. In the instance of the pragmatic trials included in this meta-analysis, this was a major issue since the secondary outcomes weren't adjusted for differences in the baseline covariates.
In addition, pragmatic trials can also be a challenge in the collection and interpretation of safety data. This is because adverse events are generally reported by the participants themselves and are prone to reporting delays, inaccuracies or coding errors. Therefore, it is crucial to improve the quality of outcome assessment in these trials, ideally by using national registries instead of relying on participants to report adverse events on the trial's database.
While the definition of pragmatism doesn't require that all clinical trials be 100% pragmatist there are benefits to including pragmatic components in trials. These include:
Enhancing sensitivity to issues in the real world, reducing study size and cost and allowing the study results to be more quickly translated into actual clinical practice (by including patients who are routinely treated). However, pragmatic trials can also have disadvantages. For example, the right type of heterogeneity could help a trial to generalise its findings to a variety of patients and settings; however, the wrong type of heterogeneity can reduce assay sensitivity, and thus reduce the power of a study to detect even minor effects of treatment.
Numerous studies have attempted to classify pragmatic trials with a variety of definitions and scoring systems. Schwartz and Lellouch1 have developed a framework that can differentiate between explanation studies that support a physiological or clinical hypothesis and pragmatic studies that inform the selection of appropriate treatments in real world clinical practice. The framework was comprised of nine domains evaluated on a scale of 1-5 which indicated that 1 was more lucid while 5 was more practical. The domains included recruitment and setting, delivery of intervention, flexible adherence, follow-up and primary analysis.
The original PRECIS tool3 was built on the same scale and domains. Koppenaal et al10 devised an adaptation of this assessment dubbed the Pragmascope that was easier to use in systematic reviews. They discovered that pragmatic systematic reviews had a higher average scores across all domains but lower scores in the primary analysis domain.
This difference in primary analysis domain can be due to the way in which most pragmatic trials analyse data. Certain explanatory trials however, do not. The overall score for systematic reviews that were pragmatic was lower when the domains of organisation, flexible delivery and follow-up were merged.
It is important to note that a pragmatic trial does not necessarily mean a poor quality trial, and there is an increasing number of clinical trials (as defined by MEDLINE search, however this is not specific or sensitive) which use the word "pragmatic" in their title or abstract. The use of these terms in titles and abstracts may suggest a greater awareness of the importance of pragmatism, but it isn't clear if this is reflected in the content of the articles.
Conclusions
As appreciation for the value of evidence from the real world becomes more popular, pragmatic trials have gained momentum in research. They are clinical trials that are randomized which compare real-world treatment options instead of experimental treatments in development. They have patients that are more similar to those treated in routine care, they use comparators that are used in routine practice (e.g., existing medications) and depend on participants' self-reports of outcomes. This method can help overcome the limitations of observational research, like the biases that are associated with the reliance on volunteers, and the lack of codes that vary in national registers.
Other advantages of pragmatic trials are the ability to use existing data sources, and a greater likelihood of detecting meaningful changes than traditional trials. However, pragmatic tests may have some limitations that limit their validity and generalizability. For instance, participation rates in some trials could be lower than anticipated due to the healthy-volunteer influence and incentives to pay or compete for participants from other research studies (e.g., industry trials). The necessity to recruit people in a timely fashion also limits the sample size and impact of many pragmatic trials. Certain pragmatic trials lack controls to ensure that any observed variations aren't due to biases that occur during the trial.
The authors of the Pragmatic Free Trial Meta identified RCTs published from 2022 to 2022 that self-described as pragmatic. The PRECIS-2 tool was used to determine the degree of pragmatism. It covers areas such as eligibility criteria and flexibility in recruitment as well as adherence to interventions and follow-up. They discovered that 14 of the trials scored as highly or pragmatic sensible (i.e. scoring 5 or more) in any one or more of these domains and that the majority were single-center.
Trials with a high pragmatism score tend to have higher eligibility criteria than traditional RCTs which have very specific criteria that are not likely to be found in the clinical setting, and comprise patients from a wide range of hospitals. The authors claim that these characteristics could make the pragmatic trials more relevant and useful for daily practice, but they do not guarantee that a pragmatic trial is free from bias. The pragmatism principle is not a fixed attribute; a pragmatic test that does not possess all the characteristics of an explanation study could still yield reliable and beneficial results.